prp
sc
believ
serv
templat
convers
prp
c
abnorm
isoform
process
requir
contact
two
protein
impli
may
critic
contact
site
import
convers
hypothes
antibodi
bind
either
prp
c
prp
sc
would
hinder
prevent
format
prp
c
prp
sc
complex
thu
slow
prevent
convers
process
two
system
use
analyz
effect
differ
antibodi
prp
sc
format
neuroblastoma
cell
persist
infect
mouseadapt
scrapi
stain
ii
protein
misfold
cyclic
amplif
pmca
use
prp
sc
templat
seed
seri
incub
sonic
convert
prp
c
prp
sc
two
system
yield
similar
result
case
demonstr
prpspecif
monoclon
antibodi
mab
vari
abil
inhibit
prp
c
prp
sc
convers
process
base
numer
vari
mab
analyz
inhibitori
effect
appear
epitop
specif
relat
prp
c
conform
cell
membran
local
influenc
target
prp
region
amino
vs
carboxi
prion
diseas
group
fatal
neurodegen
disord
associ
conform
convers
cellular
prion
protein
prp
c
mainli
ahel
beta
sheet
bsheetrich
form
prp
sc
mechan
prp
c
convert
abnorm
isoform
still
clear
presum
involv
prp
c
prp
sc
complex
latter
serv
conform
templat
model
prp
sc
serv
templat
bind
prp
c
produc
conform
convers
abnorm
isoform
rais
issu
whether
critic
contact
site
mediat
convers
case
interf
block
complex
format
prevent
prp
c
prp
sc
convers
process
previou
report
describ
antiprp
antibodi
stop
hinder
convers
process
add
refer
renumb
protein
misfold
cyclic
amplif
pmca
assay
mimic
prp
sc
propag
process
cellfre
condit
method
prp
sc
amplifi
convert
prp
c
prp
sc
seed
incub
period
sonic
prp
sc
gener
pmca
infecti
wildtyp
anim
indefinit
propag
preserv
properti
origin
prp
sc
strain
furthermor
pmca
quit
use
studi
cofactor
influenc
prp
convers
detect
prp
sc
biolog
sampl
human
anim
hypothes
antibodi
bind
prp
c
andor
prp
sc
might
hinder
prevent
format
prp
c
prp
sc
complex
thu
prevent
convers
process
compar
effect
individu
prpspecif
monoclon
antibodi
mab
prp
c
prp
sc
convers
process
use
cell
cultur
model
testtub
pmca
system
result
demonstr
mab
rang
inhibitori
effect
prp
c
prp
sc
convers
process
degre
inhibit
mab
specif
depend
antibodi
target
region
specif
epitop
recogn
furthermor
sinc
pmcabas
method
dosedepend
rapid
may
serv
ideal
screen
assay
potenti
inhibitor
prp
sc
accumul
progress
prion
diseas
procedur
involv
anim
care
conduct
accord
unit
state
depart
agricultur
anim
welfar
act
nation
institut
health
polici
human
care
use
laboratori
anim
tissu
sampl
uninfect
prion
agentinfect
mice
hamster
obtain
use
protocol
approv
institut
anim
care
use
committe
suni
downstat
medic
center
protocol
normal
hamster
brain
homogen
nbh
prepar
phosphat
buffer
salin
pb
contain
triton
edta
proteas
inhibitor
cocktail
abcam
prpspecif
mab
gener
recombin
murin
hamster
prp
brainderiv
proteinas
k
pk
resist
purifi
prp
sc
brain
clinic
mice
infect
mouseadapt
scrapi
strain
clinic
hamster
infect
hamsteradapt
scrapi
strain
mab
use
studi
purifi
montag
antibodi
purif
kit
millipor
billerica
ca
isotyp
elisa
mous
antibodi
isotyp
kit
thermo
fisher
rockford
il
epitop
map
tabl
immunoreact
mab
analyz
western
blot
denatur
pkdigest
undigest
prp
deriv
uninfect
infect
brain
homogen
well
elisa
recombin
prp
except
mab
individu
mab
equival
immunoreact
murin
hamster
prp
sc
immunoglobulin
concentr
basi
mab
highli
reactiv
hamster
prp
c
prp
sc
isoform
pmca
studi
individu
ad
nbh
final
concentr
mgml
brain
homogen
prepar
pb
dilut
final
concentr
ml
aliquot
homogen
initi
combin
ml
nbh
without
ad
mab
sampl
sonic
qsonic
power
amplitud
j
energi
sec
process
time
sec
puls
sec
puls
incub
hr
defin
one
cycl
serial
pmca
spmca
complet
cycl
addit
ml
nbh
without
mab
ad
end
everi
five
cycl
ml
total
volum
transfer
new
tube
contain
equal
volum
nbh
without
mab
cycl
reaction
continu
complet
cycl
spmca
ml
sampl
pktreat
mgml
final
concentr
min
follow
addit
proteas
inhibitor
cocktail
sampl
heat
min
centrifug
min
room
temperatur
supernat
combin
laemmli
sampl
buffer
ml
electrophores
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
follow
transfer
nitrocellulos
membran
membran
block
hr
pb
contain
tween
pbst
nonfat
dri
milk
incub
mgml
biotinyl
mab
membran
wash
time
min
pbst
incub
min
hrpconjug
streptavidin
invitrogen
pbst
contain
nonfat
dri
milk
follow
addit
pbst
wash
detect
protein
ecl
supersign
west
dura
kit
thermo
fisher
quantif
prp
sc
perform
densitometr
analysi
use
nih
imag
j
softwar
cellulos
membran
spot
overlap
prp
peptid
produc
previous
describ
membran
block
nonfat
dri
milktrisbuff
salin
contain
tween
tbst
probe
antibodi
dilut
normal
goat
serumtb
overnight
follow
horseradish
peroxidas
hrp
conjug
goat
antimous
secondari
cappel
hour
room
temperatur
detect
use
millipor
immobilon
western
chemiluminesc
hrp
substrat
cat
membran
regener
reus
shake
dimethylformamid
minut
trishcl
ph
bmercaptoethanol
bmc
sd
overnight
follow
min
wash
buffer
twice
minut
methanolglaci
acet
acid
final
three
time
minut
methanol
air
dri
membran
store
seal
contain
room
temperatur
murin
neuroblastoma
cell
atcc
line
ccl
grown
minim
essenti
medium
supplement
fb
penicillin
streptomycin
infect
brain
homogen
describ
previous
follow
infect
amount
prp
sc
mg
cell
lysat
aliquot
cell
determin
pk
digest
mgml
pk
min
sdspage
tristricin
gel
western
blot
analysi
previous
describ
treatment
cell
mab
cell
fifth
passag
infect
higher
plate
sixwel
plate
cell
confluent
mab
ad
final
concentr
mgml
incub
continu
hr
mab
test
three
independ
experi
use
independ
infect
cell
line
experi
includ
posit
control
untreat
cell
neg
control
cell
subject
pk
digest
level
pkresist
prp
sc
measur
western
blot
use
hrpconjug
sheep
antimous
igg
secondari
reagent
ecl
supersign
west
dura
kit
membran
expos
xray
film
xomat
blue
kodak
new
ct
constant
exposur
time
sec
film
convert
eightbit
grayscal
digit
file
quantif
prp
sc
perform
densitometr
analysi
use
nih
imag
j
softwar
v
area
curv
three
prp
band
repres
non
monoand
diglycosyl
isoform
protein
summar
sampl
calcul
total
amount
prp
express
percentag
averag
valu
posit
control
untreat
wherea
optic
densiti
background
taken
neg
control
lane
cell
prpspecif
mab
evalu
abil
prevent
prp
c
prp
sc
convers
linear
epitop
span
entir
prion
protein
amino
carboxi
terminu
tabl
fig
use
cell
persist
infect
mouseadapt
scrapi
strain
evalu
affect
mab
prp
sc
format
fig
treatment
mab
result
cytotox
cell
throughout
incub
period
incub
cell
mgml
purifi
irrelev
mous
igg
effect
prp
sc
format
compar
untreat
cultur
fig
mab
reduc
prp
sc
format
compar
control
cultur
lack
mab
mab
react
mous
prion
protein
surpris
abil
singli
ad
mab
inhibit
prp
sc
format
relat
specif
epitop
sinc
remain
singli
ad
mab
inhibit
prp
sc
format
vari
degre
individu
ad
mab
effect
inhibit
prp
sc
format
inhibit
least
effect
inhibit
target
amino
terminu
mab
effect
inhibit
prp
sc
format
target
octapeptid
repeat
region
use
mab
result
almost
inhibit
strang
although
epitop
overlap
mab
less
effect
mab
inhibit
prp
sc
format
vs
inhibit
contrast
mab
overlap
epitop
expans
result
inhibit
respect
combin
result
addit
inhibitori
effect
fact
result
less
inhibit
either
one
alon
confirm
studi
addit
caus
prp
sc
inhibit
slightli
better
alon
although
predict
addit
inhibitori
effect
three
mab
combin
plu
combin
observ
studi
perform
pmca
determin
whether
cellfre
system
recapitul
effect
mab
prp
c
convers
observ
infect
cell
system
also
allow
us
evalu
whether
access
mab
membran
associ
prp
c
live
cell
influenc
prp
c
prp
sc
convers
process
mab
mgml
final
concentr
ad
throughout
spmca
protocol
along
nbh
spike
dilut
infect
brain
homogen
describ
method
section
dilut
infect
brain
homogen
result
detect
pk
resist
prp
sc
immunostain
fig
therefor
interfer
detect
newli
form
prp
sc
complet
spmca
sampl
digest
pk
mgml
analyz
immunoblot
use
biotinyl
mab
react
equal
hamster
prp
c
prp
sc
interest
note
although
brain
homogen
display
band
pattern
typic
multipl
glycosyl
form
prp
c
prp
sc
fig
spmca
product
posit
control
mabtreat
reaction
consist
singl
diglycosyl
kda
prp
sc
band
observ
pk
digest
higher
level
inhibit
two
band
smear
less
inhibit
fig
pmca
presenc
mab
also
use
studi
import
bind
site
specif
prp
c
prp
sc
convers
process
fig
perform
spmca
differ
mab
concentr
determin
minimum
amount
mab
necessari
inhibit
convers
process
use
dilut
hamster
brain
homogen
prp
sc
seed
normal
brain
homogen
nbh
sourc
prp
c
test
abil
mab
inhibit
convers
prp
c
prp
sc
mab
final
concentr
mgml
lane
mgml
lane
mgml
lane
prepar
hamster
nbh
use
spmca
reaction
compar
spmca
contain
mab
lane
except
major
prpspecif
mab
inhibit
convers
process
doserel
manner
although
effect
other
mab
complet
inhibit
convers
process
mgml
mab
inhibit
convers
process
lesser
degre
inhibit
caus
mab
specif
respons
sinc
spmca
studi
replac
mab
purifi
normal
mous
igg
mgml
nbh
caus
inhibit
prp
sc
format
data
shown
interest
note
except
epitop
mab
caus
complet
inhibit
locat
amino
half
prp
caus
incomplet
inhibit
locat
carboxi
half
prp
good
correl
extent
prp
sc
inhibit
mgml
mab
cell
cultur
compar
mgml
mab
spmca
separ
studi
use
spmca
demonstr
mab
caus
complet
inhibit
prp
sc
format
mgml
fig
therefor
extend
studi
evalu
effect
mab
use
wider
rang
mab
concentr
mgml
compar
antibodi
studi
mab
pronounc
effect
prp
sc
format
demonstr
low
concentr
mgml
respect
caus
complet
inhibit
fig
potent
inhibitori
effect
prp
sc
observ
use
spmca
coincid
dramat
effect
cultur
model
furthermor
poor
prp
sc
inhibit
spmca
fig
correspond
well
poor
inhibit
reduct
compar
neg
control
observ
cell
cultur
system
fig
current
effect
treatment
prion
diseas
date
hundr
chemic
compound
identifi
antagon
prion
propag
vitro
cell
culturebas
assay
andor
vivo
anim
studi
unfortun
mani
compound
effici
vitro
studi
effect
anim
model
treatment
begun
close
time
inocul
infecti
agent
furthermor
mani
candid
compound
limit
use
clinic
due
toxic
inabl
cross
bloodbrain
barrier
eg
congo
red
iododoxorubicin
bsheet
breaker
addit
therapeut
andor
prophylact
strategi
continu
pursu
vaccin
recombin
mous
prp
delay
onset
prion
diseas
mice
passiv
immun
antiprp
antibodi
shown
inhibit
format
prp
sc
cellfre
system
also
shown
prevent
infect
suscept
cell
inhibit
prion
replic
infect
cell
effect
treatment
also
depend
administ
rel
time
infect
initi
passiv
immun
studi
use
wildtyp
mice
mab
mous
prp
residu
mous
prp
residu
given
immedi
challeng
scrapi
intraperiton
ip
inject
mgweek
result
signific
prolong
incub
period
treat
anim
remain
diseas
free
group
challeng
lower
dose
prp
sc
anoth
studi
use
higher
antibodi
dose
mgweek
ip
either
icsm
mous
prp
residu
icsm
mous
residu
prion
infect
peripher
sourc
complet
prevent
treatment
continu
day
immedi
follow
prp
sc
challeng
furthermor
transgen
mous
model
express
mab
resist
prion
infect
via
ip
inject
mechan
involv
either
perturb
cellular
prp
traffickingprp
c
degrad
disrupt
prp
c
prp
sc
interact
previou
studi
report
portion
prp
c
region
prp
import
gener
prp
sc
rigter
et
al
found
two
high
affin
bind
region
proteinprotein
interact
use
ovin
peptidearray
sheepprp
peptid
includ
aminotermin
octarepeat
ii
sheepprp
peptid
figur
repres
western
blot
prp
sc
western
blot
quantit
amount
inhibit
determin
rel
control
cultur
control
consist
cell
absenc
mab
presenc
normal
mous
igg
prp
sc
inhibit
plot
repres
mean
sd
three
independ
experi
describ
method
encompass
scrapi
susceptibilityassoci
polymorph
sheep
moroncini
et
al
found
residu
within
segment
prp
c
key
compon
prp
c
prp
sc
complex
beringu
et
al
report
antibodi
exclus
bind
prp
c
rel
ineffici
inhibitor
prp
sc
accumul
compar
antibodi
addit
recogn
diseaseassoci
prp
isoform
et
al
screen
antiprp
mab
capac
inhibit
prp
sc
replic
infect
cell
identifi
four
differ
linear
epitop
hinder
prp
c
prp
sc
convers
amino
termin
region
octarepeat
region
intermedi
region
central
region
observ
antibodi
bind
amino
terminu
prion
protein
capabl
inhibit
convers
suggest
figur
western
blot
brain
homogen
use
seed
pmca
dilut
brain
homogen
prepar
either
untreat
lane
pktreat
lane
prior
sdspage
western
blot
dilut
prior
pk
demonstr
three
protein
band
pattern
typic
brain
homogen
wherea
band
visibl
dilut
homogen
b
western
blot
pmca
product
follow
absenc
presenc
prpspecif
mab
fourti
cycl
serial
pmca
carri
absenc
presenc
mab
describ
text
mab
ad
final
concentr
mg
ml
follow
pk
treatment
pmca
product
subject
sdspage
western
blot
immunostain
prpsc
protein
band
quantit
level
prpsc
inhibit
rel
mab
normal
mous
igg
control
determin
figur
influenc
mab
prp
sc
format
follow
spmca
mab
ad
spmca
final
concentr
mgml
pmca
product
pk
treat
western
blot
prp
sc
quantit
level
prp
sc
inhibit
determin
rel
control
reaction
endogen
proteolyt
cleavag
occur
site
convers
complet
explor
possibl
therapeut
effect
antiprp
antibodi
establish
anoth
system
analyz
influenc
ab
convers
process
screen
mab
produc
laboratori
capac
inhibit
prp
sc
format
screen
perform
use
cell
cellfre
spmca
cultur
mab
react
mous
prp
reduc
prp
sc
format
although
vari
effici
thu
similar
previou
result
found
abil
inhibit
prp
c
prp
sc
convers
restrict
singl
epitop
limit
specif
region
protein
howev
greatest
inhibit
observ
mab
target
epitop
amino
termin
unstructur
region
prp
greatest
inhibit
cell
mab
consist
prior
studi
use
mab
antiprp
residu
screen
multipl
mab
one
produc
greatest
inhibit
mab
also
shown
efficaci
vivo
prolong
presymptomat
incub
period
mab
inhibit
result
obtain
use
pmca
similar
found
cell
cultur
system
pmca
advantag
cell
cultur
model
costeffect
simpl
rapid
sensit
amen
studi
dose
depend
identif
potenti
candid
mab
might
vivo
activ
like
mab
would
produc
inhibit
much
simpler
vitro
system
interact
prp
c
prp
sc
critic
depend
structur
compat
molecul
support
exist
speci
barrier
prion
infect
relat
minor
differ
primari
sequenc
prp
c
differ
speci
therefor
surpris
antibodi
may
alter
mask
critic
epitop
prp
c
andor
prp
sc
involv
mutual
conform
complementar
requir
prion
propag
inhibitori
prion
replic
although
mani
antiprp
antibodi
target
differ
region
prp
may
therapeut
effect
vitro
clear
relat
efficaci
vivo
one
hand
tempt
specul
antibodi
exhibit
near
complet
inhibit
vitro
would
effect
vivo
given
obstacl
blood
brain
barrier
access
prp
cell
howev
also
possibl
partial
inhibit
convers
requir
vivo
allow
cell
recov
either
case
would
advantag
therapeut
antibodi
high
affin
bind
prp
c
andor
prp
sc
well
target
specif
critic
prp
domain
one
hypothes
simultan
target
one
critic
epitop
lead
greater
benefit
howev
cotreat
experi
perform
mixtur
two
antibodi
compat
bind
cellsurfac
prp
c
show
benefit
compar
treatment
involv
singl
mab
current
experi
previou
studi
demonstr
synergist
bind
one
antibodi
pair
synergist
bind
inhibitori
mab
ie
reaction
antibodi
increas
bind
second
antibodi
would
predict
enhanc
inhibitori
effect
studi
antibodi
pair
fit
descript
requir
test
hypothesi
addit
determin
signific
mab
abil
bind
prp
c
prp
sc
may
provid
insight
convers
process
conceiv
design
experi
rr
tw
perform
experi
bc
rp
tw
rr
analyz
data
bc
rp
tw
rr
contribut
reagentsmaterialsanalysi
tool
rp
tw
rr
wrote
paper
rr
